Clinical trial
A Randomized, Phase 2 Study of Biomarker Guided Treatment in DLBCL
NCT04025593 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Phase 2 Study of Biomarker Guided Treatment in DLBCL
- Lead sponsor
- Ruijin Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 17, 2019
- Completion date
- June 1, 2023
- Enrollment
- 128 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse large b cell lymphoma